Breaking News

GlycoMimetics Receives $15M Pfizer Milestone

May 21, 2014

Rivipansel moves to Phase III development

GlycoMimetics, Inc. has received a $15 million payment from Pfizer under the companies’ collaboration for the development of rivipansel (GMI-1070). Pfizer plans to initiate a Phase III trial of rivipansel, which will trigger an additional $20 million milestone payment to GlycoMimetics upon dosing of the first patient in the trial.
 
“Moving into Phase III will be a significant step forward in our effort to potentially address the unmet needs of individuals with sickle cell disease. With the commitment of our collaborator, Pfizer, we hope this will enable us to bring to patients, caregivers and physicians an important new medication for treatment of vaso-occlusive crisis or VOC of sickle cell disease,” said Rachel King, chief executive officer, GlycoMimetics.
 
The companies entered the collaboration and exclusive license agreement with for rivipansel in October 2011. The companies are currently developing rivipansel as a potential treatment for VOC of sickle cell disease.

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research